Program
Sustained-Release Gemcitabine-Docetaxel NDV-01
Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Urologic Neoplasms, led by Relmada Therapeutics.
Furthest: phase 3, since Dec 29, 20253 company-led studies, 1 open or runningNext primary completion: Dec 2029 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Relmada Therapeutics | 31 open or running | phase 3since Dec 29, 2025 | Dec 29, 2025 | Dec 2029phase 3 · NCT07464145 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 29, 2025First study: phase 3 study in NeoplasmsFirst studyNCT07313891
- Jan 13, 2026Phase 3 study in NeoplasmsNCT07342517
- Mar 2, 2026Phase 3 study in NeoplasmsNCT07464145 · 393 planned
Ahead
- Dec 2029Primary completion: phase 3 study in NeoplasmsNCT07464145
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07464145Neoplasms | 3 | Not yet recruiting | Dec 2029 | 393 |
| NCT07342517Neoplasms | 3 | Withdrawn | Jun 30, 2027 | 0 |
| NCT07313891Neoplasms | 3 | Withdrawn | Sep 1, 2029 | 0 |
How it is read
Names in the registry
- “NDV-01 (sustained-release gemcitabine-docetaxel)”, 3 entries
Conditions, from the studies’ own filings
- Non-Muscle Invasive Bladder Neoplasms, 2 studies
- Urologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.